On October 6, 2025, Valneva SE secured a $500 million loan, which includes a committed $215 million Tranche A Loan for debt repayment, and expects to use the remaining funds for general corporate needs. Additionally, their Lyme disease vaccine trial is on track, with results anticipated in early 2026 and a potential product launch in late 2027, pending regulatory approval.